Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).

Clinical lung cancer - 1 Mar 2023

Raez Luis E, Brice Kayla, Dumais Katerine, Lopez-Cohen Alejandro, Wietecha Delia, Izquierdo Paola A, Santos Edgardo S, Powery Hermán W

Abstract excerpt

In the last decade, non-small-cell lung cancer (NSCLC) treatment has improved with the approval of multiple therapies to target specific genetic alterations. Though, next generation sequencing (NGS) has traditionally been conducted from tissue biopsy samples, developing data supports the use of plasma-based circulating tumor DNA (ctDNA), also known as "liquid biopsy," to complement tissue biopsy approaches in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 36585341
DOI: 10.1016/j.cllc.2022.11.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).PMID 36585341Read ↗

Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC.Semantic proximity Read ↗

Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study.Semantic proximity Read ↗

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.Semantic proximity Read ↗

Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients.Semantic proximity Read ↗

Complementing Tissue Testing with Plasma mutation Profiling Improves Therapeutic Decision Making for Lung Cancer PatientsSemantic proximity Read ↗

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.Semantic proximity Read ↗

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.Semantic proximity Read ↗

The evolving role of liquid biopsy in lung cancer.Semantic proximity Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.Semantic proximity Read ↗

Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.